Dr. Harper Grace Hubbeling, MD

Dr. Hubbeling practices at Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, part of University of Pennsylvania.

Dr. Hubbeling's NPI, 1033614623, was assigned on March 27, 2018. Dr. Hubbeling holds Pennsylvania license MD481746.

Dr. Hubbeling's primary practice is Hospital of the University of Pennsylvania, at 3400 Spruce St, Philadelphia, PA 19104 in Philadelphia County. The practice phone is (215) 662-6289.

Dr. Hubbeling's primary practice is Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, part of University of Pennsylvania. Dr. Hubbeling is also affiliated with Penn Presbyterian Medical Center. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Hubbeling to 2 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hubbeling practices, 4 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Hubbeling's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dmand AI has Dr. Hubbeling's licenses on file in 2 states: Pennsylvania and New Jersey.

CMS data shows 653 Medicare services from Dr. Hubbeling across 14 procedure codes in 2024, for 235 Medicare patients. Medicare paid $43,494 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 235 Medicare patients who saw Dr. Hubbeling in 2024. The largest group is 65 to 74, with 137 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 12% are also on Medicaid. Their average risk score is 1.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hubbeling's median patient age at 61, with 48% women.

In 2024, Dr. Hubbeling wrote 48 Medicare Part D claims for 17 patients. 100% of them were for generic drugs. CMS names the drug for 19 of them, across 1 drug with 11 or more claims each, at $157 in total drug cost. In 2023, CMS named 46 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Hubbeling for performance year 2024, reported as part of a group. Dr. Hubbeling accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hubbeling as offering telehealth.

Dmand AI links 20 papers to Dr. Hubbeling, published from 2014 to 2025. 2018 was the busiest year, with 4. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Immunotherapy, Adoptive. Dr. Hubbeling has published most often in Blood Adv. Dr. Hubbeling's most frequent co-authors are Brandon Stuart Imber, MD, Aaron N. Hata, MD, PhD and Joachim Yahalom, MD.